GTC
ALDR

Ghost Tree Capital’s Alder Biopharmaceuticals ALDR Stock Holding History

Ghost Tree Capital’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-250,000
Closed -$2.86M – 88
2017
Q2 		$2.86M Buy
+250,000
New +$4.62M 0.6% 54
2016
Q4 		– Sell
-16,000
Closed -$524K – 104
2016
Q3 		$524K Buy
+16,000
New +$487K 0.09% 82

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Ghost Tree Capital's ALDR Position: Q3 2017 in Review

Ghost Tree Capital sold out of Alder Biopharmaceuticals (ALDR) in Q3 2017, closing a stake of 250,000 shares — an estimated $2.86M sold.

Ghost Tree Capital first reported a position in ALDR in Q3 2016 and held it in 2 quarters. The position peaked at $2.86M in Q2 2017. 132 funds tracked by Wall St. Rank hold ALDR as of Q3 2017.

  • Ghost Tree Capital reported no remaining Alder Biopharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Ghost Tree Capital sold 250,000 Alder Biopharmaceuticals shares in Q3 2017, an estimated $2.86M.
  • Ghost Tree Capital first reported a position in Alder Biopharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Ghost Tree Capital's Alder Biopharmaceuticals position peaked at $2.86M in Q2 2017.
  • 132 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2017.

Based on Ghost Tree Capital's 13F filing for Q3 2017, filed 14 Nov 2017.